Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Coherus BioSciences reported a 4% increase in annual net revenue to $267 million for 2024, despite significant divestitures. UDENYCA® saw a 62% year-over-year revenue increase, while LOQTORZI® experienced a 29% quarter-over-quarter revenue rise.
March 10, 2025 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences reported a 4% increase in annual net revenue to $267 million for 2024, with significant growth in UDENYCA® and LOQTORZI® revenues.
The reported increase in annual net revenue and significant growth in key product revenues (UDENYCA® and LOQTORZI®) are positive indicators for Coherus BioSciences. This suggests strong product performance and potential for future growth, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100